Tag: GlaxoSmithKline

Bharat Biotech Acquires Manufacturer of Rabies Vaccines from GSK

Bharat Biotech announces the forthcoming acquisition of Chiron Behring Vaccines Pvt Ltd, located in Ankleshwar, Gujarat from GlaxoSmithKline Asia. Bharat Biotech will acquire 100% equity stake in Chir...

GSK and Merck to Develop Cancer Treatment under €3.7bn Deal

GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal. The M7824 is an investigational bifunctional fusion protein im...

FDA Approved Mylan’s Asthma Generic

The U.S. Food and Drug Administration (FDA) approved Mylan NV’s generic version of GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher on Wednesday....

GSK and Sanofi Take Part in FinnGen

GlaxoSmithKline and Sanofi have joined academic groups and other pharma companies to take part in Finland’s large scale genomics project, based on data from 500,000 biobank volunteers. FinnGen aims...

GSK Completed Tesaro Acquisition

British drugmaker GlaxoSmithKline (GSK) has completed the acquisition of the US-based oncology-focused biopharmaceutical firm Tesaro for $5.1bn (£4bn). Tesaro acquisition will enable GSK to strengt...

Big Pharma Companies to Raise Drug Prices in January

Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry...

New-Made Largest Over-the-Counter Products Firm in the World

GlaxoSmithKline has announced its second major deal this month, signing an agreement with Pfizer to combine its consumer health business and form a joint venture with combined annual sales of $12.7 bi...

Manufacturing of Tivicay® in Moscow will be launched no later than May 2019

GSK and Servier signed an agreement to launch the manufacturing of innovative HIV drug Tivicay® (INN: dolutegravir) in the production facility of Servier Rus pharmaceutical plant in Moscow.

GSK received approval for Shingrix vaccine in Europe and Japan

GlaxoSmithKline announced that the European Commission has approved Shingrix for the prevention of shingles and post-herpetic neuralgia. The Japanese Ministry of Health, Labour and Welfare has also approved Shingrix.

GSK brings legal action against Gilead Sciences

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Ltd., announced that it has filed patent infringement litigation against Gilead Sciences

Avara CDMO bought healthcare facility from GSK

Avara Pharmaceutical Services has signed an agreement with GSK to acquire a GSK consumer healthcare manufacturing facility

Insilico Medicine and GSK set up a collaboration focused on AI drug discovery

drug discovery
Insilico Medicine announced that it has formed a collaboration with GSK to explore how Insilico's AI capability can enhance its drug discovery process

GSK closes neuroscience R&D site in China and relocates it to USA

GlaxoSmithKline is closing its neuroscience research and development site in China and is moving it to the company’s hub in the Philadelphia which includes Conshohocken and Collegeville

Exscientia and GSK started drug discovery collaboration

Exscientia, an innovative company at the forefront of Artificial Intelligence-driven drug discovery, announced it has entered into a strategic drug discovery collaboration with GlaxoSmithKline

Teva lost a patent case to GSK and must pay $235 million

A US court yesterday ordered Teva Pharmaceutical Industries Ltd. to pay $235 million compensation to GlaxoSmithKline for violation of the latter's patent

GSK presented results of Benlysta drug study

GlaxoSmithKline announced results from study, which showed that Benlysta (belimumab) plus standard of care prolonged control of disease activity in patients with active systemic lupus erythematosus